Associated Papers
Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.
Marie V et al.
Journal of Biomolecular Structure & Dynamics, 2022
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
Blanch-Lombarte O et al.
The Journal of Antimicrobial Chemotherapy, 2020
Epistasis as a determinant of the HIV-1 protease's robustness to mutation.
Capel E et al.
Plos One, 2014
Heat shock protein 90AB1 and hyperthermia rescue infectivity of HIV with defective cores.
Joshi P et al.
Virology, 2013
Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.
Smidt W
Plos One, 2013
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
Henderson GJ et al.
Antimicrobial Agents and Chemotherapy, 2012
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I et al.
The Journal of Infection, 2007
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Cabana M et al.
Virology, 2002
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Sugiura W et al.
Antimicrobial Agents and Chemotherapy, 2002
Select a paper to view details